

Reporting period January – March

- ◆ **Orders received** increased by 2.0% to SEK 5,576 M (5,467), and rose organically by 9%
- ◆ **Net sales** decreased by 5.6% to SEK 4,863 M (5,153)
- ◆ **Profit before tax** rose by 4.0% to SEK 551 M (530)
- ◆ **Net profit** increased by 4.7% to SEK 400 M (382)
- ◆ **Earnings per share** rose by 4.7% to SEK 1.68 (1.60)
- ◆ **Excluding the currency gain of SEK 228 M, which was recognised in Q1 2009, profit before tax rose 82%**
- ◆ **EBITA before restructuring** increased by 28.2% to SEK 836 M (652)
- ◆ **Strong cash flow**
- ◆ **Earnings outlook remains strong** for 2010

First quarter 2010

Profitability improved significantly during the period in the wake of efficiency enhancements implemented in recent years. Demand, for which the trend was weak in 2009, continued to strengthen.

Orders received The Group's orders received continued to gradually improve and increased organically by 9% during the quarter. Orders received were particularly strong in Medical Systems and Infection Control, for which orders received improved organically by 14.1 and 12.1%, respectively. For Extended Care, with its greater exposure toward the elderly-care sector, which receives more local and private financing, and Northern European markets, orders received declined somewhat. Orders received in the North American market improved for all business areas and demand remains stable in Western Europe.

Results Profit before tax increased by 4% to SEK 551 M (530). Excluding the currency gain of SEK 228 M, which was included in first-quarter profit in 2009 and arose in conjunction with the acquisition of Datascope, profit before tax increased by 82%. The Group's EBITA rose 28.2% to SEK 836 M (652) and the EBITA margin was a highly favourable 17.2% (12.7). Medical Systems and Extended Care improved their operating profit significantly, while Infection Control's operating profit was somewhat lower than in the year-earlier period. Operating cash flow increased by 14.2% to SEK 1,129 M (989). Excluding the aforementioned

currency gain, operating cash flow rose 48%. The net debt/equity ratio was 1.21 (1.71) at the end of the first quarter.

Outlook

Demand for the Group's products is expected to gradually improve, following a period of lower growth. The most important contribution to this favourable volume trend is the continued improvement in the demand scenario in the North American market. Demand in Western Europe, which has been generally favourable during the past year, is expected continue growing in 2010, although at a slower pace. In the markets outside Western Europe and North America, demand and growth are expected to improve on 2009.

In terms of the Group's business areas, Medical Systems is expected to have the best growth opportunities in 2010. New and key product launches combined with revenue synergies from acquisitions in recent years will contribute to Medical Systems' growth. Infection Control is also anticipating improved volume growth in 2010, while Extended Care, which has greater exposure to the elderly-care sector, which receives more local and private financing, is expected to experience moderate growth in 2010.

Major restructuring costs in 2009, which were primarily attributable to the integration of Datascope and the Cardiac and Vascular surgery divisions, will decline considerably, while synergy gains from the actions implemented will contribute to profit growth. Favourable exchange effects are also expected to contribute to earnings growth.

Overall, the Group is expecting a good improvement in the Group's orders received and invoicing growth during the current fiscal year. Measured as profit before tax, profit growth is expected to remain strong.

Business area Medical Systems

Orders received

	2010	2009	Change adjusted for
<i>Orders received per market</i>	3 mon	3 mon	<i>curr.flucs.&corp.acqs.</i>
Europe	977	1 053	-0,4%
USA and Canada	843	865	4,6%
Asia and Australia	476	486	-6,5%
Rest of the world	552	196	184,9%
Business area total	2 848	2 599	14,1%

The business area's orders received increased organically by 14.1% during the quarter. The volume trend was particularly favourable for Critical Care and Surgical Workplaces.

Orders received in Western Europe were comparable with the year-earlier period. In Scandinavia, Benelux and in German-speaking markets, orders received improved during the period, while there was a decline in the UK and Southern and Eastern Europe.

Volume growth improved in North America in line with the trend that has been noticeable since autumn 2009.

Orders received in emerging markets were mixed with strong growth in Southeast Asia and South America, while Middle Eastern and African markets were weaker. A major ventilator order from Brazil was secured during the period.

Results

	2010	2009	Change	2009
	3 mon	3 mon		FY
Net sales, SEK million	2 451	2 453	-0,1%	11 255
<i>adjusted for currency flucs. & corp.acqs</i>			6,2%	
Gross profit	1 414	1 385	2,0%	6 343
Gross margin %	57,7%	56,5%	1,2%	56,4%
Operating cost, SEK million	-1 023	-1 137	-10,0%	-4510
EBITA before restructuring and integration costs	485	346	40,2%	2 231
EBITA margin %	19,8%	14,1%	5,7%	19,8%
Restructuring and integration costs	-8	-11		-197
EBIT	382	237	60,5%	1 636
EBIT margin %	15,6%	9,7%	5,9%	14,5%

EBITA prior to restructuring costs rose by 40.2% to SEK 485 M (346). The improvement in operating profit was attributable to increased organic invoicing growth and efficiency-enhancements in the wake of acquisitions that were integrated during the past year. Earnings include the previously reported capital gain of SEK 42 M, which arose in conjunction with the divestment of a product-development project to Thoratec, a US company. The Datascope acquisition, which has been incorporated with Medical

Systems since February 2009, contributed three-months' earnings during the quarter compared with two months in the year-earlier period. The EBITA margin prior to restructuring costs was a highly favourable 19.8% (14.1). Restructuring costs during the period amounted to SEK 8 M (11).

Activities

Integration of Datascope

Efforts to integrate Datascope's operation into the business area's existing structure have been completed in all material respects. The remaining integration work pertains to transferring Datascope's operations to Medical Systems' existing IT environment. Integration costs of SEK 8 M were charged to the quarter. The remaining costs, which will be charged to 2010, are expected to amount to SEK 17 M.

Product launches

The commercialisation of the business area's heart-lung support product Cardiohelp is proceeding as planned. In the second quarter of 2010, clinical evaluations will commence at a number of hospitals. Cardiohelp is a portable ECMO product that can temporarily assume control of the heart and/or lung functions to ensure a patient's survival or to allow the heart or lungs the opportunity to recover.

During the period, the business area initiated user-validation testing on the FLOW-i anaesthesia system. Validation testing is underway at a number of hospitals throughout Europe. A number of patients have already undergone anaesthesia treatments using FLOW-i with highly favourable results. The product has continued to receive very strong reviews from clinical personnel.

The business area initiated a partnership with Philips to develop what are known as hybrid operating theatres. The partnership enables the integration of Philips' Allura Xper radiology imaging system with Medical Systems' solutions and equipment for operating theatres.

Business area Extended Care

Orders received

	2010	2009	Change adjusted for
Orders received per market	3 mon	3 mon	<i>curr.flucs.&corp.acqs.</i>
Europe	859	990	-3,1%
USA and Canada	448	479	4,6%
Asia and Australia	138	138	-4,2%
Rest of the world	29	37	-21,3%
Business area total	1 474	1 644	-1,4%

Orders received declined organically by 1.4% during the period. Extended Care's lower orders received compared with the Group's other business areas was attributable to the business area's higher exposure to customers in the elderly-care sector, and the greater dependence, in relative terms, on the UK and Northern Europe markets.

The volume trend in the Southern and Central Europe markets and in North America was generally good.

In the emerging markets, orders received improved in Southeast Asia and Latin America, while Middle Eastern and African markets reported a decline in orders received during the period.

Results

	2010	2009	Change	2009
	3 mon	3 mon		FY
Net sales, SEK million	1 447	1 649	-2,2%	6 467
<i>adjusted for currency flucs. & corp.acqs</i>			-3,5%	
Gross profit	729	755	-3,4%	2 964
Gross margin %	50,4%	45,8%	4,6%	45,8%
Operating cost, SEK million	-468	-553	-15,3%	-2074
EBITA before restructuring and integration costs	287	231	24,3%	1 002
EBITA margin %	19,8%	14,0%	5,8%	15,5%
Restructuring and integration costs	-3	-26		-55
EBIT	258	176	46,7%	835
EBIT margin %	17,8%	10,7%	7,1%	12,9%

EBITA prior to restructuring costs improved by 24.3% amounting to SEK 287 M (231). Taking into account the organic decline in invoicing volumes during the period, earnings were considered very favourable. The improvement in earnings was attributable to continued efficiency enhancements in the business pertaining to production and the marketing organisation. A stronger product mix with less emphasis on beds, contributed to improving the gross margin. The EBITA margin was a highly favourable 19.8% (14) during the quarter.

Activities

Restructuring activities

The merger of the business area's sales companies in the UK

During the quarter, the business area announced that it was assessing a merger of the business area's two sales companies in the UK with the aim creating a more effective organisation. Combined, the UK and the US comprise the business area's single largest market, employing about 1,000 individuals.

Merger of the business area's sales companies in France

As previously announced, Extended Care has initiated a merger of the business area's two French sales companies. The effort is proceeding as planned. Costs for the merger are expected to amount to about SEK 24 M and were charged to earnings in 2009. The merger is expected to generate an annual improvement in earnings of SEK 15 M as of 2011.

Product launches

During the period, Extended Care launched Maxi Once. MaxiOnce is a disposable sliding aid that was developed to facilitate bed transfers in hospital wards with a large turnover of patients and high requirements for protection against the transmission of diseases.

Business area Infection Control

Orders received

	2010	2009	Change adjusted for
<i>Orders received per market</i>	3 mon	3 mon	<i>curr.flucs.&corp.acqs.</i>
Europe	664	665	9,6%
USA and Canada	349	381	5,1%
Asia and Australia	208	159	31,8%
Rest of the world	32	19	73,8%
Business area total	1 253	1 224	12,1%

Infection Control's orders received increased organically by 12.1% and all geographic regions reported strong growth.

In Europe, growth was strong in markets in Central and Southern Europe, while growth in the UK declined somewhat.

Other markets in Europe were on par with the year-earlier period. In North America, volumes continued to improve for life science and the healthcare market.

In the emerging markets, orders received were favourable.

Results

	2010	2009	Change	2009
	3 mon	3 mon		FY
Net sales, SEK million	965	1 051	-8,2%	5 094
<i>adjusted for currency flucs. & corp.acqs</i>			1,5%	
Gross profit	367	391	-6,1%	1 945
Gross margin %	38,0%	37,2%	0,8%	38,2%
Operating cost, SEK million	-307	-321	-4,3%	-1261
EBITA before restructuring and integration costs	64	74	-14,4%	700
EBITA margin %	6,6%	7,0%	-0,5%	13,7%
Restructuring and integration costs	-	-		-85
EBIT	60	70	-14,6%	599
EBIT margin %	6,2%	6,7%	-0,5%	11,8%

EBITA prior to restructuring costs for the quarter were somewhat lower than in the year-earlier period, which was attributable to weak volume growth. The EBITA margin was comparable to the year-earlier level amounting to 6.6% (7) during the seasonally weak quarter.

Activities**Restructuring activities**

As previously announced, the business area intends to discontinue production at its units in Peiting in Germany and Lynge in Denmark, and relocate these to Sweden, to Växjö and Getinge, respectively. The aim of the production relocations is to concentrate the business area's production to fewer and more efficient production facilities. During the quarter, the planned production relocations were initiated and work proceeded as planned. Costs for the planned activities, which were provisioned in the financial statements of 2009, are expected to amount to about SEK 85 M and to generate annual savings of about SEK 40 M as of 2011.

Acquisition of Odelga

During the quarter, the business area acquired the Austrian company Odelga. The company, with operations in Graz and Vienna, has a significant service organisation and supplies sterilisation equipment to hospitals and the Life Science industry. Odelga had sales of EUR 2.4 M in 2009 and has 12 employees. The acquisition will strengthen Infection Control's exposure to Central Europe.

Other information

Accounting

This interim report was prepared for the Group in accordance with the IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report was prepared in accordance with the Swedish Annual Accounts and RFR 2.2.

New accounting principles in 2010

In accordance with disclosure in the Annual Report, Note 1, regarding new accounting principles for 2010, a number of new standards and IFRIC interpretations became effective January 1, 2010.

Revised IFRS 3 Business combinations

The standard became effective on July 1, 2009 and applies to fiscal years beginning on or after that date. The standard entails changes to the reporting of future acquisitions regarding for example the accounting of transaction costs, any contingent considerations and step acquisitions. Further information is available in note 1 to the consolidated financial statements, included in the 2009 Annual Report for the Getinge Group,

IAS 27 amendment Consolidated and separate financial statements

The standard became effective on July 1, 2009, as a consequence of the revised IFRS 3, and applies to fiscal years beginning on or after that date. The amendment introduces changes in IAS 27 regarding for example how to report changes to the ownership in cases where the parent company retains or loses the control of the owned entity. The Group will apply the amendment as of January 1, 2010. The application will prospectively affect the accounting for business combinations made from the application date.

The above mentioned amendments and other new amendments to standards and IFRIC interpretations applied by the Getinge Group from January 1, 2010, have not had any significant effect on the financial statements of the Group during the first quarter 2010.

Otherwise, accounting principles and methods of calculations have remained essentially unchanged from those applied in the 2009 Annual Report.

This report has not been specifically audited by Getinge's auditors.

Risk management

Political decisions altering the healthcare reimbursement system represent the single greatest risk to the Getinge Group. The risk to the Group as a whole is limited by the fact that Getinge is active in a large number of countries. The Group's operational risks are limited, since as a rule its customers' operations are funded directly or indirectly from public funds. The Group's Risk Management team works continuously to minimise the risk of production disruptions.

Financial risk management. Getinge is exposed to a number of financial risks in its operations. "Financial risks" refer primarily to risks related to currency and interest rates as well as credit risks. Risk management is regulated by a financial policy established by the Board of Directors. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with

Group management and the treasury function. The main financial risks to which the Group is exposed are currency risks, interest-rate risks, and credit and counterparty risks.

Forward-looking Information

This report contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (Q2 2010) will be published on 12 July 2010.

Teleconference

A telephone conference will be held on 21 April at 2:00 p.m. Swedish time. To participate, please call:
Within Sweden: +46 (0)8 506 269 30
UK: +44 207 750 9950

Agenda:

1:45 p.m. Call the conference number
2:00 p.m. Review of the interim report
2:20 p.m. Questions
3:00 p.m. End

A recorded version of the conference will be available for five working days at the following numbers:

Sweden: +46 (0)8 506 269 49
UK: +44 207 750 99 28
Code: 241148#

During the telephone conference, a presentation will be held. To gain access to this presentation, please click on the following link:
<https://www.anywhereconference.com/?Conference=108241148&PIN=599764>

The Board of Directors and CEO ensure that the interim report provides a true and fair overview of the Parent Company and the Group's operations, position and earnings and describes the material risks faced by the Parent Company and the Group.

Getinge 21 April 2010

Carl Bennet
Chairman

Johan Bygge

Rolf Ekedahl

Jan Forslund

Carola Lemne

Margareta Norell Bergendahl

Bo Sehlin

Johan Stern

Johan Malmquist
CEO

Getinge AB
Box 69, 310 44 Getinge
Telephone: +46 (0)35-15 55 00. Fax: +46 (0)35-549 52
e-mail info@getinge.com
Corp. Reg. No. 556408-5032
www.getingegroup.com

The information given here is information that Getinge AB is obligated to publish under the Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act.

Consolidated Income statement

SEK million	2010 3 mon	2009 3 mon	Change	2009 FY
Net sales	4 863	5 153	-5,6%	22 816
Cost of goods sold	-2 353	-2 622	-10,2%	-11 564
Gross profit	2 510	2 531	-0,8%	11 252
<i>Gross margin</i>	51,6%	49,1%	2,5%	49,3%
Selling expenses	-1 153	-1 257	-8,3%	-4 957
Administrative expenses	-576	-587	-1,9%	-2 333
Research & development costs ¹	-109	-160	-31,9%	-539
Restructuring and integration costs	-11	-37	-70,3%	-336
Other operating income and expenses	40	-6	-766,7%	-17
Operating profit ²	701	484	44,9%	3 070
<i>Operating margin</i>	14,4%	9,4%	5,0%	13,5%
Financial Net, SEK ³	-150	46		-436
Profit before tax	551	530	4,0%	2 634
Taxes	-151	-148		-720
Net profit	400	382	4,7%	1 914
Attributable to:				
Parent company's shareholders	400	382		1 911
Minority interest	0	0		3
Net profit	400	382		1 914
Earnings per share, SEK ⁴	1,68	1,60	4,7%	8,02

1 Development costs totalling SEK 185 (123) million have been capitalised during the quarter

2 Operating profit is charged with

— amort. Intangibles on acquired companies	-124	-131		-527
— amort. intangibles	-52	-42		-177
— depr. on other fixed assets	-160	-172		-672
	-336	-345		-1 376

3 Financial net income

— currency gains	0	228		228
— net of interest incomes, interest expenses and other financial expenses	-150	-182		-664
	-150	46		-436

4 There are no dilutions

Comprehensive earnings statement

	2010	2009
M kr	3 mon	3 mon
Profit for the period	400	382
Other comprehensive earnings		
Translation differences	-427	499
Cash-flow hedges	144	-288
Income tax related to other partial result items	-38	76
Other comprehensive earnings for the period, net after tax	-321	287
Total comprehensive earnings for the period	79	669
Comprehensive earnings attributable to:		
Parent Company shareholders	79	669
Minority interest	-	-

Quarterly results

	2008	2008	2008	2008	2009	2009	2009	2009	2010
SEK million	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1
Net sales	4 107	4 451	4 291	6 423	5 153	5 524	5 294	6 845	4 863
Cost of goods sold	-2 040	-2 260	-2 276	-3 362	-2 622	-2 873	-2 605	-3 464	-2 353
Gross profit	2 067	2 191	2 014	3 061	2 531	2 651	2 689	3 381	2 510
Operating cost	-1 500	-1 539	-1 496	-1 801	-2 047	-2 016	-1 953	-2 165	-1 809
Operating profit	545	554	518	1 260	484	635	736	1 216	701
Financial net	-182	-174	-190	-204	46	-172	-164	-146	-150
Profit before tax	363	380	328	1 056	530	463	572	1 070	551
Taxes	-103	-108	-93	-298	-148	-130	-160	-282	-151
Profit after tax	260	272	235	758	382	333	412	788	400

Consolidated Balance sheet

Assets SEK million	2010	2009	2009
	31 Mar	31 Mar	31 Dec
Intangible fixed assets	20 203	21 596	20 353
Tangible fixed assets	3 450	3 912	3 674
Financial assets	1 136	1 240	1 135
Stock-in-trade	4 249	4 795	4 156
Current receivables	6 046	7 194	6 791
Cash and cash equivalents	1 258	1 676	1 389
Total assets	36 342	40 413	37 498
Shareholders' equity & Liabilities			
Shareholders' equity	12 641	11 345	12 562
Long-term liabilities	18 249	22 250	19 494
Current liabilities	5 452	6 818	5 442
Total Equity & Liabilities	36 342	40 413	37 498

Consolidated Cash flow statement

SEK million	2010 3 mon	2009 3 mon	2009 FY
<i>Current activities</i>			
EBITDA	1 037	829	4 446
Restructuring Cost expenses	11	37	336
Restructuring costs paid	-59	-14	-202
Adjustment for items not included in cash flow	21	3	41
Financial items	-150	-182	-436
Currency Gain	1	228	-
Taxes paid	-16	-150	-653
Cash flow before changes in working capital	845	751	3 532
<i>Changes in working capital</i>			
Stock-in-trade	-191	-392	-6
Current receivables	632	978	745
Current operating liabilities	-157	-348	-271
Cash flow from operations	1 129	989	4 000
<i>Investments</i>			
Acquisition of subsidiaries	-10	-5 050	-5 072
Other acquisition expenses	-	-391	-484
Capitalized development costs	-185	-123	-585
Rental equipment	-47	-67	-249
Investments in tangible fixed assets	-134	-298	-907
Cash flow from investments	-376	-5 929	-7 297
<i>Financial activities</i>			
Change in interest-bearing debt	-1 136	6 056	2 712
Change in long-term receivables	79	-156	119
New share issue	-	-	-
Dividend paid	-	-	-572
Other	2	-	-
Cash flow from financial activities	-1 055	5 900	2 259
Cash flow for the period	-302	960	-1 038
Cash and cash equivalents at begin of the year	1 389	1 506	1 506
Translation differences	171	-790	921
Cash and cash equivalents at end of the period	1 258	1 676	1 389

Consolidated Net interest-bearing debt

SEK million	2010 31 Mar	2009 31 Mar	2009 31 Dec
Debt to credit institutions	14 985	19 279	16 052
Provisions for pensions, interest-bearing	1 565	1 763	1 634
Less liquid funds	-1 258	-1 676	-1 389
Net interest-bearing debt	15 292	19 366	16 297

Changes to shareholders' equity

SEK million	Share capital	Other contributed capital	Reserves	Profit brought forward	Total	Minority interests	Total equity
Opening balance on 1 January 2009	107	5 972	-572	5 145	10 652	24	10 676
Total comprehensive earnings for the period			287	382	669		669
Closing balance on 31 March 2009	107	5 972	-285	5 527	11 321	24	11 345
Opening balance on 1 January 2010	119	5 960	-25	6 484	12 538	24	12 562
Total comprehensive earnings for the period			-321	400	79		79
Closing balance on 31 March 2010	119	5 960	-346	6 884	12 617	24	12 641

Key figures

	2010	2009	Change	2008	2009
	3 mon	3 mon		3 mon	FY
Orders received, SEK million	5 576	5 467	2,0%	4 666	23 036
adjusted for currency flucs.& corp.acqs			9,0%		
Net sales, SEK million	4 863	5 153	-5,6%	4 107	22 816
adjusted for currency flucs.& corp.acqs			2,1%		
EBITA before restructuring- and integration costs	836	652	28,2%	649	3 933
EBITA margin before restructuring- and integration costs	17,2%	12,7%	4,5%	15,8%	17,2%
Restructuring and integration costs	11	37		23	336
EBITA	825	615	34,1%	626	3 597
EBITA margin	17,0%	11,9%	5,1%	15,2%	15,8%
Earnings per share after full tax, SEK	1,68	1,60	4,7%	1,09	8,02
Number of shares, thousands	238 323	238 323	0,0%	201 874	238 323
Interest cover, multiple	5,7	4,2	35,7%	4,1	5,5
Operating capital, SEK million	28 875	23 277	24,0%	16 542	23 771
Return on operating capital, per cent	12,5%	12,7%	-0,2%	15,4%	13,3%
Return on equity, per cent	15,3%	19,9%	-4,6%	20,1%	16,6%
Net debt/equity ratio, multiple	1,21	1,71	-29,2%	1,64	1,30
Cash Conversion	108,9%	119,4%	-10,5%	69,8%	90,0%
Equity/assets ratio, per cent	34,8%	28,1%	6,7%	28,2%	33,5%
Equity per share, SEK	52,90	47,50	11,4%	38,77	52,60

Five-year review

	2010	2008	2007	2006	2005
SEK million	31 Mar	31 Mar	31 Mar	31 Mar	31 Mar
Net Sales	4 863	5 153	4 107	3 415	2 975
Profit before tax	400	382	260	203	191
Earnings per share	1,68	1,60	1,29	1,00	0,93

Income statement for the parent company

	2010	2009	2009
M kr	3 mon	3 mon	FY
Administrative expenses	-40	-29	-124
Operating profit	-40	-29	-124
Financial net	124	-127	1 453
Profit after financial items	84	-156	1 329
Profit before tax	84	-156	1 329
Taxes	-22	39	-149
Net profit	62	-117	1 180

Balance sheet for the parent company

	2010	2009	2009
Assets SEK million	31 Mar	31 Mar	31 dec
Tangible fixed assets	33	33	34
Shares in group companies	5 705	4 796	5 685
Long-term financial receivables	0	19	0
Deferred tax asset	34	27	34
Receivable from group companies	25 815	25 933	27 556
Short-term receivables	31	129	48
Total assets	31 618	30 937	33 357
Shareholders' equity & Liabilities			
Shareholders' equity	7 471	6 942	7 382
Long-term liabilities	14 347	17 875	15 425
Untaxed reserves	34	0	34
Current liabilities	9 766	6 120	10 516
Total Equity & Liabilities	31 618	30 937	33 357

Information pertaining to the Parent Company's development during the January – March 2010 reporting period

Income statement At the end of the period, receivables and liabilities in foreign currencies were valued at the closing-day rate and an unrealised gain of SEK 97 M is included in the period's net financial items.

Companies acquired in 2009

Odelga

In early 2010, Infection Control acquired the Austrian service company Odelga, which generated sales of about SEK 25 M in the most recent financial year. The total price of the acquisition was about SEK 10 M.

Acquired net assets and goodwill in conjunction with the acquisition

SEK M Net assets	Balance sheet at the time of acquisition
Tangible assets	1
Inventories	2
Other current assets	3
Cash and cash equivalents	5
Provisions	-4
Current liabilities	-5
	2
Goodwill	8
Total acquisitions with cash and cash equivalents	10

Net outflow of cash and cash equivalents due to the acquisition

Cash and cash equivalents paid for the acquisition	10
Cash and cash equivalents in the acquired company at the date of acquisition	-5
	5

Goodwill that arose in conjunction with the transaction was attributable to ancillary sales of Infection Control's products in Austria.

The company is included in Getinge's sales and operating profit since of 1 March 2010.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortisation of intangible assets identified in conjunction with corporate acquisitions.
BRIC	Brazil, Russia, India, China